Dupilumab-Associated Severe Headaches in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP): A Report of Two Cases With Resolution After Cessation
Abstract
Dupilumab is a monoclonal antibody that targets interleukin (IL)-4 and IL-13, approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). While common adverse effects such as conjunctivitis and injection-site reactions are well characterized, headaches reported in clinical trials are typically described as mild, non-specific, and rarely treatment-limiting. We describe two patients with CRSwNP who developed severe, recurrent headaches shortly after initiating dupilumab therapy. In one case, symptoms improved after discontinuation and recurred upon rechallenge; in the other, the headaches resolved after discontinuation. These observations raise the possibility that dupilumab-associated headaches may occasionally be more severe than previously appreciated. Clinicians should be aware of this potential association when evaluating new-onset headaches in patients receiving dupilumab.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.